AnGes
4563.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Operating income | −¥5.1bn | −¥9.1bn | −¥12.0bn | −¥16.3bn | −¥15.6bn | — |
| Ordinary income | −¥5.3bn | −¥7.5bn | −¥5.7bn | −¥14.6bn | −¥13.6bn | −¥6.6bn |
| Net income (owners) | −¥5.1bn | −¥28.1bn | −¥7.4bn | −¥14.7bn | −¥13.7bn | −¥4.2bn |
| Total assets | ¥5.4bn | ¥4.7bn | ¥28.9bn | ¥38.8bn | ¥45.5bn | ¥38.4bn |
| Net assets / equity | ¥3.1bn | ¥2.2bn | ¥26.1bn | ¥30.4bn | ¥38.6bn | ¥32.7bn |
| Operating cash flow | −¥5.8bn | −¥6.6bn | −¥8.7bn | −¥11.2bn | −¥11.4bn | −¥3.0bn |
| EPS (basic) | ¥-14.44 | ¥-119.53 | ¥-39.29 | ¥-94.29 | ¥-92.86 | ¥-35.33 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 62 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 170 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 170 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 62 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 38 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 170 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 40 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 64 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 38 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 168 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3Amended | 40 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 40 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 64 figures · EDINET |
24 more reports are still being processed.